advertisement
 

  Back to Alternative Medicine Main Page Complementary and Alternative Medicine

References

Links to abstracts or books are included when possible.

  1. Josefson D. Complementary medicine is booming worldwide. BMJ. 1996;313:131-133.
  2. Marwick C. Alterations are ahead at the OAM. JAMA. 1998;280:1553-1554.
  3. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med. 1993;328:246-352.
  4. Miller LG, Hume A, Mehra Harris I, et al. White paper on herbal products. Pharmacotherapy. 2000;20:877-891.
  5. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998;280:1569-1575.
  6. Sabo CE, Rush Michael S, Temple LL. The use of alternative therapies by diabetes educators. Diabetes Educ. 1999;25:945-946;949-950;952-954;956.
  7. Gill GV, Redmond S, Garratt F, Paisey R. Diabetes and alternative medicine: cause for concern. Diabet Med. 1994;11:210-213.
  8. Astin JA. Why patients use alternative medicine - results of a national study. JAMA. 1998;279:1548-1553.
  9. Elder NC, Gillcrist A, Minz R. Use of alternative health care by family practice patients. Arch Fam Med. 1997;6:181-184
  10. Anderson DL, Shane-McWhorter L, Crouch B, Andersen SJ. Alternative medication use in rheumatology and geriatric patients. Pharmacotherapy. 2000;8:958-966.
  11. Shaw D, Leon C, Koley S, Murray V. Traditional remedies and food supplements: a 5-year toxicological study (1991-1995). Drug Saf. 1997;17:342-356.
  12. Boullata JI, Nace AM. Safety issues with herbal medicine. Pharmacotherapy. 2000;20:257-269.
  13. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med. 1998;158:220-222.
  14. Fugh-Berman A. Herb-drug interactions. Lancet.2000;355:134-138.
  15. Bonati A. How and why should we standardize phytopharmaceutical drugs for clinical validation? J Ethnopharmacol. 1991;32:195-197.
  16. Grant KL. Patient education and herbal dietary supplements. Am J Health-Syst Pharm. 2000;57:1997-2003.
  17. Nortier JL, Muniz Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342:1686-1692.
  18. U.S. Food and Drug Administration: Regulation on statements made for dietary supplements concerning the effect of the product on the structure or function of the body. Federal Register. January 6, 2000;65:1000-1050.
  19. Norcross WA, Ganiats TG, Ralph LP, Seidel RG, Ikeda TS. Accidental poisoning by warfarin-contaminated herbal tea. Western J Med. 1993;159:80-82.
  20. Blumenthal M. Industry alert: plantain adulterated with digitalis. Herbal Gram. 1997;350:1598-1599.
  21. U.S. Food and Drug Administration. Dietary supplement strategy (ten year plan). Center for Food Safety and Applied Nutrition. Washington, DC, January 2000. Available at: http://vm.cfsan.fda.gov/~dms/ds-strat.html.
  22. Sarubin A. The Health Professional's Guide to Popular Dietary Supplements. Chicago, IL: American Dietetic Association; 2000.
  23. Blumenthal M, Busse WR, Goldberg A, et al. eds. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S.Klein. Boston, MA: American Botanical Council; 1998.
  24. The Review of Natural Products by Facts and Comparisons. St Louis, Mo: Wolters Kluwer Co; 1999.
  25. Jellin JM, Batz F, Hitchens K. Pharmacist's Letter/Prescribers Letter Natural Medicines Comprehensive Database. Stockton, Ca: Therapeutic Research Faculty; 2000.
  26. Kapoor LD. Handbook of Ayurvedic Medicinal Plants. Boca Raton, Fl: CRC Press Inc; 1990:200-201.
  27. Shanmugasundaram ER, Panneerselvam C, Samudram P, Shanmugasundaram ERB: Enzyme changes and glucose utilisation in diabetic rabbits: the effect of gymnema sylvestre. J Ethnopharmacol 1983;7:205-34.
  28. Persaud SJ, Al-Majed H, Raman A, Jones PM. Gymnema sylvestre stimulates insulin release in vitro by increased membrane permeability. J Endocrinol. 1999;163:207-212.
  29. Shanmugasundaram ERB, Gopinath KL, Radha Shanmugasundaram KR, Rajendran VM. Possible regeneration of the islets of langerhans in streptozotocin-diabetic rats given gymnema sylvestre leaf extracts. J Ethnopharmacol. 1990;30:265-279.
  30. Shanmugasundaram ERB, Rajeswari G, Baskaran K, et al. Use of gymnema sylvestre leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus. J Ethnopharmacol. 1990;30:281-294.
  31. Baskaran K, Kizar B, Ahamath K, Radma Shanmugasundaram K, Shanmugassundaram ERB. Antidiabetic effect of a leaf extract from gymnema sylvestre in non-insulin-dependent diabetes mellitus patients. J Ethnopharmacol. 1990;30:295-306.
  32. Madar Z. Fenugreek (trigonella foenum-graceum) as a means of reducing postprandial glucose levels in diabetic rats. Nut Rep Inter. 1984;29:1267-1273.
  33. Raghuram TC, Sharma R, Sivakumar D, Sahay BK. Effect of fenugreek seeds on intravenous glucose disposition in non-insulin dependent diabetic patients. Phytotherapy Research. 1994;8:83-86.
  34. Patil SP, Niphadkar PV, Bapat MM. Allergy to fenugreek (trigonella foenum graecum). Ann Allergy Asthma Immunol. 1997;78:297-300.
  35. Sharma RD, Raghuram TC, Sudhakar Rao N. Effect of fenugreek seeds on blood glucose and serum lipids in type 1 diabetes. Eur J Clin Nutr. 1990;44:301-306.
  36. Madar Z, Abel R, Samish S, Arad J. Glucose-lowering effect of fenugreek in non-insulin dependent diabetics. Eur J Clin Nutr. 1988;42:51-54.
  37. Sharma RD, Sarkar A, Hazra DK, et al. Use of fenugreek seed powder in the management of non-insulin-dependent diabetes mellitus. Nutr Res. 1996;16:1331-1339.
  38. Ali, K, Khan AK, Mamum MI, Mosihuzzaman M, Nahar N, Nur-e-Alam M, Rokeya B: Studies on hypoglycaemic effects of fruit pulp, seed, and whole plant of momordica charantia on normal and diabetic model rats. Planta Med 1993;56:408-12.
  39. Aslam M, Stockley IH: Interaction between curry ingredient (karela) and drug (chlorpropamide). Lancet. 1979;i:607.
  40. Ahmad N, Hassan MR, Halder H, Bennoor KS. Effect of momordica charantia (karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients. Bangladesh Med Res Counc Bull. 1999;25:11-13.
  41. Khanna P, Jain SC, Panagariya A, Dixit VP. Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod. 1981;44:648-655.
  42. Akhtar MS. Trial of momordica charantia linn (karela) powder in patients with maturity-onset diabetes. J Pak Med Assoc. 1982;32:106-107.
  43. Raman A, Houston P. Herbal products - ginseng. Pharm J. 1995;255:150-152.
  44. Vogler BK, Pittler MH, Ernst E. The efficacy of ginseng, a systematic review of randomized clinical trials. Eur J Clin Pharmacol. 1999;55:567-575.
  45. Vuksan V, Sievenpiper JL, Koo VY, et al. American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med. 2000;160:1009-1013
  46. Siegel RK. Ginseng abuse syndrome: problems with the panacea. JAMA. 1979;241:1614-1615.
  47. Cui J, Garle M, Eneroth P, Bjorkhem I. What do commercial ginseng preparations contain? [letter] Lancet. 1994;344:134.
  48. Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulin dependent diabetic patients. Diabetes Care. 1995;18:1373-1375.
  49. Ibanez-Camacho R, Roman-Ramos R. Hypoglycemic effect of opuntia cactus. Arch Invest Med. 1979;10:223-230.
  50. Frati-Munari AC, Gordillo BE, Altaminrano P, Ariza CR. Hypoglycemic effect of Opuntia streptacantha Lemaire in NIDDM. Diabetes Care. 1988;11:63-66.
  51. Frati AC, Gordillo BE, Altamirano P, Ariza CR, Cortes-Franco R, Chavez-Negrete A. Acute hypoglycemic effect of opuntia streptacantha lemaire in NIDDM. [letter] Diabetes Care. 1990;13:455-456.
  52. Ghannam N. The antidiabetic activity of aloes: preliminary clinical and experimental observations. Horm Res. 1986;24:288-294.
  53. Muth ER, Laurent JM, Jasper P. The effect of bilberry nutritional supplementation on night visual acuity and contrast sensitivity. Altern Med Rev. 2000;5:164-173.
  54. Pepping J. Alternative therapies-milk thistle: silybum marianum. Am J Health-Syst Pharm. 1999;56:1195-1197.
  55. Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol. 1997;26:871-879.
  56. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (silybum marinum) for the therapy of liver disease. Am J Gastroenterol. 1998;93:139-143.
  57. Food and Nutrition Board. Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington DC: National Academy Press; 2001.
  58. Anderson R, Polansky M, Bryden N, Canary J. Supplemental chromium effects on glucose, insulin, glucagon, and urinary chromium losses in subjects consuming controlled low-chromium diets. Am J Clin Nutr. 1991;54:909-916.
  59. Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improves glucose and insulin variables in individuals with type 2 diabetes. Diabetes. 1997; 46:1786-1791.
  60. Cefalu WT, Bell-Farrow AD, Stegner J, et al. Effect of chromium picolinate on insulin sensitivity in vivo. J Trace Elem Exp Med. 1999;12:71-83.
  61. Jovanovic L, Gutierrez M, Peterson CM. Chromium supplementation for women with gestational diabetes mellitus. J Trace Elem Exp Med. 1999;12:91-07.
  62. Abraham AS, Brooks BA, Eylath U. The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. Metabolism. 1992;41:768-71.
  63. Uusitupa MJ, Mykkanen L, Siitonen O, Laakso M, Sarlund H, Kolehmainen P, Rasanen T, Kumpulainen J, Pyorala K. Chromium supplementation in impaired glucose tolerance of elderly: effects on blood glucose, plasma insulin, C-peptide and lipid levels. Br J Nutr. 1992;68:209-216.
  64. Fawcett JP, Farquhar SJ, Walker RJ, Thou T, Lowe G, Goulding A. The effect of oral vanadyl sulfate on body composition and performance in weight-training athletes. Int J Sport Nutr. 1996;6:382-390.
  65. Fantus IG, Tsiani E. Multifunctional actions of vanadium compounds on insulin signaling pathways: Evidence for preferential enhancement of metabolic versus mitogenic effects. Mol Cell Biochem. 1998;182:109-119.
  66. Cohen N, Halberstam M, Shlimovich P, Chang CJ, Shamoon H, Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1995;95:2501-2509.
  67. Domingo JL, Gomez M, Llobet JM, Corbella J, Keen CL: Oral vanadium administration to streptozotocin-diabeic rats has marked negative side effects which are independent of the form of vanadium used. Toxicology 1991;66:279-87.
  68. Boden G, Chen X, Ruiz J, van Rossum GDV, Turco Sl. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin dependent diabetes mellitus. Metabolism. 1996;45:1130-1135.
  69. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. Metabolic effects of sodium metavanadate in humans with insulin-dependent and non-insulin-dependent diabetes mellitus: In vivo and in vitro studies. J Clin Endrocrinol Metab. 1995;80:3311-3320.
  70. Pepping J. Alternative therapies - Coenzyme Q10. Am J Health-Syst Pharm. 1999;56:519-521.
  71. McCarty MF: Can correction of sub-optimal coenzyme Q status improve beta-cell function in type II diabetics? Med Hypotheses 1999;52:397-400.
  72. Shigeta Y, Izumi K, Abe H. Effect of coenzyme Q7 treatment on blood sugar and ketone bodies of diabetics. J Vitaminol. 1966;12:293-298.
  73. Henriksen JE, Andersen CB, Hother-Nielsen O, et al. Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with type 1 diabetes mellitus. Diabetic Med. 1999;16:312-318.
  74. Elliott RB, Pilcher CC, Fergusson DM et al. A population-based strategy to prevent insulin-dependent diabetes using nicotinamide. J Pediatr Endocrinol Metab. 1996;501-509.
  75. Pozzilli P, Browne PD, Kolb H and the Nicotinamide Trialists. Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. Diabetes Care. 1996;19:1357-1363.
  76. Polo V, Saibene A, Pontiroli AE. Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas. Acta Diabetol. 1998;35:61-64.
  77. Head KA. Type 1 diabetes: prevention of the disease and its complications. Alt Med Rev. 1997;2:256-281.
  78. Schatz DA, Rogers DG, Brouhard BH. Prevention of insulin-dependent diabetes mellitus: an overview of three trials. Cleveland Clinic Journal of Medicine. 1996;63:270-274.
  79. Nichols TW. Alpha-lipoic acid: Biological effects and clinical implications. Alt Med Rev. 1997;2:177-183.
  80. Evans JL, Goldfine ID: alpha-Lipoic Acid: a multi-functional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technol Ther 2000;2:401-13.
  81. Packer L. Antioxidant properties of lipoic acid and its therapeutic effects in prevention of diabetes complications and cataracts. Ann NY Acad Sci.1994;738:257-264.
  82. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care.1996;19:257-267.
  83. Ziegler D, Hanefeld M, Ruhnau K-J, et al, The ALADIN Study Group. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study I). Diabetologia. 1995;38:1425-1433.
  84. Reljanovic M, Reichel G, Rett K, et al, and the ALADIN II Study Group. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo controlled trial (ALADIN II). Alpha Lipoid Acid in Diabetic Neuropathy. Free Radic Biol Med. 1999;31:171-179.
  85. Ziegler D, Hanefeld M, Ruhnau K-J, et al. The ALADIN III Study Group: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid. a 7-month multicenter randomized controlled trial (ALADIN III Study). Diabetes Care. 1999;22:1296-1301.
  86. Ziegler D, Reljanovic M, Mehnert H, Gries FA: Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999;107:421-30.
  87. Jamal GA, Carmichael H. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabetic Medicine. 1990;7:319-323.
  88. The Gamma-Linolenic Acid Multicenter Trial Group, Keen H, Payan J, Allawi J, et al. Treatment of diabetic neuropathy with gamma-linolenic acid. Diabetes Care. 1993;16:8-15.
  89. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet. 1992;340:1136-1139.
  90. Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta analysis of randomized trials. Am J Med. 2000;108:276-281.
  91. Cohen AJ, Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther. 1998;24:139-143.
  92. Shon M, Sikora R. Ginkgo biloba extract in the therapy of erectile dysfunction. J Sex Ed Ther. 1991;17:53-61.
  93. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia. North American Egb Study Group. JAMA. 1997;278:1327-1332.
  94. Castleman M. The Healing Herbs. Emmaus, PA: Rodale Press; 1991.
  95. Pareddy SR, Rosenberg JM. Does garlic have useful medicinal purposes? Hospital Pharmacist Report. 1993;8:27.
  96. Rose KD, Croissant PD, Parliament CF, Levin MB. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery. 1990;2:880-882.
  97. German K, Kumar U, Blackford HN. Garlic and the risk of TURP bleeding. [letter] Br J Urol. 1995;76:518.
  98. Burnham BE: Garlic as a possible risk for postoperative bleeding. [letter] Plast Reconstr Surg. 1995;95:213.
  99. Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterolemia, a meta-analysis of randomized clinical trials. Ann Intern Med. 2000;133:420-429.
  100. Silagy CA, Neil HA. A meta-analysis of the effect of garlic on blood pressure. J Hypertens. 1994;12:463-468.
Go To Main Page ...

Complementary and Alternative Medicine Pages:
Main | Concerns | Gymnema Sylvestre | Fenugreek | Bitter Melon | Ginseng | Nopal | Aloe, Bilberry, and Milk Thistle | Chromium | Vanadium | CoQ10 | Nicotinamide | Alpha Lipoic Acid | Gamma Linolenic Acid | Ginkgo Biloba | Garlic | Advice | Additional Reading | References

Laura Shane-McWhorter, PharmD, BCPS, FASCP, CDE, BC-ADM
November 24, 2001



                 
  Home Return to Top

Last Updated: Wednesday December 31, 2014 20:55:34
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2015. Comments and Feedback.